Treatments for multiple myeloma have advanced rapidly over the past 15 years as research has fostered an improved understanding of the mechanisms of the disease. These discoveries have been translated into effective drugs, most notably bortezomib (Velcade), thalidomide (Thalomid), and lenalidomide (Revlimid).
Several new regimens with bortezomib (Velcade) are currently being investigated in combination with different agents for various subpopulations of patients with multiple myeloma or were presented at ASCO 2011.
Bortezomib and Dexamethasone
Bortezomib is currently approved for the treatment of multiple myeloma. Because twice-weekly bortezomib is associated with toxicity such as neuropathy, some studies are investigating new regimens with only once-weekly administration of the drug.
Results 1 - 2 of 2